Stoke Therapeutics, Inc. announced enrollment of the first patient in an observational study of children and adolescents ages 2 to 18 with Dravet syndrome. BUTTERFLY is a two-year observational study that is designed to evaluate seizure frequency and non-seizure comorbidities associated with the disease, including motor and speech impairment, intellectual and developmental disabilities, behavioral deficits and abnormal sleep patterns. Data from the study will support clinical development plans for the company’s lead therapeutic candidate, STK-001, an investigational new treatment for Dravet syndrome.
September 12, 2019
Diacomit is Effective as Add-on Therapy to Reduce Refractory Seizures in Dravet, Review Study Finds
Diacomit is a new type of anticonvulsive medication that has been shown to reduce the frequency of seizures in patients with Dravet syndrome, especially when administered in combination with other antiseizure medications or with dietary interventions.